Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.
BAL8557 is the water-soluble prodrug of a novel antifungal triazole, BAL4815. BAL4815 is active against a broad spectrum of major opportunistic and pathogenic fungi, including strains that are resistant to other azoles. Cohorts of healthy male subjects received single-ascending oral (p.o.) doses of BAL8557 that were equivalent to 100, 200, or 400 mg of BAL4815 or single-ascending, 1-h constant-rate intravenous (i.v.) infusions of BAL8557 which were equivalent to 50, 100, or 200 mg of BAL4815. In each cohort, six subjects were randomly assigned to receive active drug and two subjects were assigned to receive the placebo. All doses were well tolerated, and no severe or serious adverse events occurred. Maximum plasma concentrations of BAL4815 were observed 1.5 to 3 h after p.o. drug intake or at the end of the 1-h infusion. After both routes of administration, values for maximum drug concentration observed in plasma and area under the concentration-time curve increased slightly more than proportionally to the administered dose. Mean elimination half-lives were particularly long (56 to 77 h after p.o. administration and 76 to 104 h after i.v. administration). The volume of distribution was large (155 to 292 liters after p.o. administration and 304 to 494 liters after i.v. administration) and systemic clearance was low (1.9 to 2.8 liter/h after p.o. administration and 2.8 to 5.0 liter/h after i.v. administration). Urinary recovery of BAL4815 was less than 0.4% of the infused dose. Based on the exposure data, oral bioavailability of BAL4815 is assumed to be very high. The pharmacokinetics of BAL4815 are well suited to maintaining concentrations of BAL4815 for a long period of time in the body and to enabling an effective treatment of systemic mycoses.
Schmitt-Hoffmann
Anne
A
Basilea Pharmaceutica, Ltd., P.O. Box 3255, 4002 Basel, Switzerland. schmita@basileapharma.com
Roos
Brigitte
B
Heep
Markus
M
Schleimer
Michael
M
Weidekamm
Erhard
E
Brown
Tom
T
Roehrle
Michael
M
Beglinger
Christoph
C
D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001682:Biological Availability; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005658:Fungi / Q000187:drug effects*; D006207:Half-Life; D064368:Healthy Volunteers; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D011355:Prodrugs / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D012449:Safety; D014230:Triazoles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*
D000935:Antifungal Agents; D009570:Nitriles; D011355:Prodrugs; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole